Close
Solutions
Online Inquiry
Global Services

TCR-Like Antibody Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Equipped with high-end technologies and Ph.D. level scientists, Creative Biolabs has long been a famous service provider in the field of antibody development and immunotherapy. After years of exploration, now, we are proud to introduce our innovated TCR-like antibody services, ranging from immunogen production to antibody characterization. We are aiming to accelerate therapeutic antibody drug development for a better tomorrow.

1. Introduction of TCR-Like Antibody

TCR-Like Antibody Services

TCR-like antibodies, or TCRm antibodies, are antibodies with T cell receptor-like specificities. Since they allow, for the first time, visualization of MHC/peptide complexes on various cells in health and disease, they belong to a new class of antibodies which can be utilized as important tools in molecular immunology. Meanwhile, these antibodies allow the determination of the expressed tumor or viral-related MHC/peptide complexes on the surface of primary tumor cells and metastases or viral infected cells, antigen-presenting cells, etc. Therefore, they help to shed new light on the process of antigen presentation on tumor and viral infected cells. Moreover, TCR-like antibodies lead to new opportunities for antibody-based targeting approaches, by constructing recombinant immunotoxins, fusions with cytokine molecules, or for bi-specific antibody therapy. In addition, they are also helpful in structural and functional studies of TCR-peptide-MHC interactions. For short, they serve as a valuable tool in various pathological conditions such as cancer, viral infections, and autoimmune disease, not only at the level of the T-cell using MHC-tetramers, but also at the level of the APC and diseased cell.

2. One-Stop Service Package in Creative Biolabs

Given to the importance of TCR-like antibodies, now, Creative Biolabs brings up a one-stop pipeline to help our worldwide customers discover these promising antibodies.

a. MHC/Peptide Complex Production for TCR-Like Antibody Discovery

Immunogen preparation is one of the main limitations in TCR-like antibody discovery. With the help of extensive experience, Creative Biolabs has built up a high-throughput MHC-associated peptide screening platform to identify the peptides which are presented by antigen-presenting cells to T cells in just 3-4 weeks. Besides, we have succeeded in many cases to express and purify functional MHC/peptide complexes in bacterial system. Of note, we can also provide eukaryotic systems (yeast cells, insect cells, mammalian cells) upon request.

b. TCR-Like Antibody Discovery Strategies

Antibodies with MHC-restricted specificity of T cells have been traditionally rare and difficult to generate. However, Creative Biolabs offers both hybridoma technology and phage display technology to fulfill this purpose. Multiple immunization hosts are available, even including several unique transgenic mice, which can be used to obtain fully human antibodies without further in vitro humanization. Particularly, some premade human libraries can be used for phage display to shorten your project timeline and make it more competitive.

c. TCR-Like Antibody Affinity Characterization

Due to the high-affinity feature, affinity characterization is quite important to verify the quality of TCR-like antibody. We offer different approaches (SPR, BLI, and ITC) to perform the measurement. These are all label-free methods which are convenient to use. Our well-trained technicians and skillful scientists will work together to provide you high-quality and reliable results.

d. TCR-Like CAR Construction and Evaluation Service

Since there are two CAR-T cell therapies approved by FDA, more and more promising CARs are under-development. We are also capable of constructing TCR-like CAR-T to put your project more closer to clinical study. At the same time, evaluation assays either in vivo or in vitro can be designed according to your targets and downstream applications.

TCR-Like Antibody Services

3. Highlight Features of Our Service

➢ One-stop package
Our one-stop package covers the whole process of TCR-like antibody discovery. Customized project design will meet all your specific requirement.

➢ All-round platforms
We offer several superior technology platforms. Prokaryotic and eukaryotic expression systems, hybridoma technology, phage display technology, humanized mice, versatile QC technologies, etc are all ready-to-use on our platforms.

➢ Flexible labeling
Flexible labeling (biotin, fluorescent tags, and more) of antigens and antibodies are also on our service list to satisfy your demands.

➢ Experienced scientific team
We are good at timely troubleshooting to put each project closer to success.

If you are interested in any of our service, please feel free to contact us by e-mail and our team will get back to you as soon as possible.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.